Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
about
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaRegorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsThe dual role of tumor lymphatic vessels in dissemination of metastases and immune response developmentContrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancerSHP-1 is a target of regorafenib in colorectal cancer.Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal CancerRegorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.An update on the safety and efficacy of regorafenib in the treatment of solid cancers.Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.Regorafenib in the treatment of colorectal cancer.A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.Effect of oncogene activating mutations and kinase inhibitors on amino acid metabolism of human isogenic breast cancer cells.Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
P2860
Q26741651-0EED2B97-0800-46E9-9BE9-5731A1B26FB4Q26784091-0C34C508-2452-40A7-AA2F-FE5D83F44DA7Q27345024-A8EF7F86-C632-4E69-A6C4-8CA54AAEFF5DQ28076945-7918752D-4CC4-4554-AE59-AF8DA8054F44Q30365404-486B45BD-7874-4958-B32A-AEFAB908BC43Q33441453-73E8B0DC-F5C4-41E9-B97F-0E3028B2BA25Q34227671-2488F895-455A-43DF-89EC-4E65AD90DB82Q35783407-B46212E6-203F-47CB-8DCE-CB31CF8980CDQ35869753-F1B157DC-1242-4072-AE43-A2ECAEDBCCCCQ36078348-AFFBC31F-1A98-490A-81F5-A1EAFD0EC599Q36223964-1E76FDF4-940D-4E52-9B9F-C78A1C78811FQ37211199-C02F7325-7310-4FF9-B2E1-3C6E8A0A2845Q37429966-7C757DD2-3056-4838-A85D-A2946A004F6AQ38260324-61883FB8-CCA7-4FD3-8A68-F3A5BE66372FQ38496239-AE205FFE-1083-4E93-8B2C-B7A3E851B13AQ38630817-4FE4A380-5338-455A-913A-C6CE91E58839Q38646622-9363F806-46D2-4E4D-81A3-CDF4F47EAB74Q38827757-61717013-EF68-42A7-B55D-7A143AD9E7F9Q38831467-28EB8813-56C1-4430-BB63-582BF0C971FEQ38854561-F73FED1A-D76A-4DA1-8B93-655686FEAFCFQ41194627-C0288AD8-044A-4965-A145-67E2F47A6306Q42366615-4B55AEBB-B80F-4EEF-8BD7-FE97BAAAB6BDQ50673610-EF8660B4-EFC6-41E2-928D-B850F29AC400Q52643766-9CD05300-A6EA-4948-8E01-7F16FB1BA6CFQ53097666-9767F8A4-4278-44B7-B666-104FC5A1F7E1Q59138354-31EF2CDE-1114-4012-8D4E-C5FB82823BF1
P2860
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@ast
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@en
type
label
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@ast
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@en
prefLabel
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@ast
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@en
P2093
P2860
P356
P1476
Regorafenib (BAY 73-4506): ant ...... l models of colorectal cancer.
@en
P2093
Ajay Bhargava
André Rosenthal
Arne Scholz
Dieter Zopf
Jens Hoffmann
Karl-Heinz Thierauch
Michael Becker
Nicole Kahmann
Peter Ellinghaus
Robert Adams
P2860
P304
P356
10.1002/IJC.28669
P577
2014-04-17T00:00:00Z